Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
October 2025
The Middle East and Africa life science market size was estimated at US$ 4.47 billion in 2024, projected to increase to US$ 5.04 billion in 2025 and reach US$ 13.07 billion by 2034, showing a healthy CAGR of 11.32% across the forecast years.
The Middle East and Africa life science market is experiencing robust growth driven by increasing government healthcare investments, expanding biotechnology and pharmaceutical sectors, and rising demand for advanced diagnostics and research capabilities. GCC countries, particularly the UAE and Saudi Arabia, are leading with strong R&D infrastructure, digital health adoption, and partnerships with global life science firms, positioning the region as a growing hub for medical innovation and biomanufacturing.
| Table | Scope |
| Market Size in 2025 | USD 5.37 Billion |
| Projected Market Size in 2034 | USD 18.82 Billion |
| CAGR (2025 - 2034) | 16.75% |
| Market Segmentation | By Product Type, By Application, By End-User, By Technology, By Region |
| Top Key Players | Illumina, Inc., QIAGEN, PerkinElmer (Revvity), Lonza Group, Sartorius AG, Charles River Laboratories, Eurofins Scientific |
The market is growing due to rising healthcare investments, expanding biopharma production, and increasing demand for advanced medical research and diagnostics. The Middle East and Africa Life Science Market refers to the ecosystem of products, services, and technologies that support biological research, healthcare, biotechnology, pharmaceuticals, diagnostics, and laboratory services across the region. It encompasses drug development, genomics, proteomics, diagnostics, digital health, and research tools, addressing unmet medical needs and advancing scientific innovation in MEA’s evolving healthcare and research landscape.
The Middle East and Africa life science market is expanding due to increasing government healthcare spending, advancements in biotechnology, rising prevalence of chronic diseases, and growing collaborations with global pharmaceutical and research organizations aimed at improving regional healthcare infrastructure.
AI can significantly transform the Middle East and Africa life science market by enabling personalized wellness and fitness solutions, predictive health monitoring, and smart nutrition planning. It enhances e-commerce experiences through targeted recommendations, optimizes supply chains for lifestyle products, and supports virtual consultations in beauty, fitness, and healthcare sectors. Additionally, AI-driven data analytics helps businesses understand consumer behavior, improving product development and marketing strategies, ultimately boosting market growth and consumer engagement.
In 2024, the reagents & consumables segment is projected to lead the Middle East and Africa life science market as rising focus on innovative research, vaccine development, and personalized medicine fuels demand. Expansion of diagnostic centers, adoption of miniaturized and automated lab techniques, and increasing investment in academic and private research institutions contribute to consistent usage. Their critical role in enabling rapid, accurate experiments and supporting a variety of applications across biotechnology and clinical testing underpins the segment’s dominant market position.
The software & information segment is expected to grow rapidly in the Middle East and Africa life science market as organizations increasingly adopt cloud-based platforms, telehealth analytics, and bioinformatics tools. Enhanced data integration, remote collaboration, and digital tracking of clinical trials are driving demand, while government initiatives promoting smart healthcare and investment in AI-powered research infrastructure further accelerate the adoption of software and information solutions across the region.
The clinical diagnostics segment dominated the Middle East and Africa life science market as healthcare providers increasingly rely on advanced testing to improve patient outcomes. Investments in modern laboratory infrastructure, rising demand for high-throughput and rapid diagnostic solutions, and government programs supporting public health screening have driven growth. Moreover, the expansion of specialized diagnostic centers and the adoption of innovative technologies like liquid biopsies and immunoassays have strengthened the segment’s market position across the region.
The cell & gene therapy research segment is projected to register the fastest growth in the Middle East and Africa life science market, as growing collaborations between biotech firms and academic institutions accelerate innovation. Increasing focus on regenerative medicine, rare disease treatments, and clinical trial initiatives, along with rising availability of specialized laboratory infrastructure and funding programs, is driving adoption. Moreover, technological advancements in gene delivery systems and global partnerships are further fueling the rapid expansion of this segment across the region.
The pharmaceutical & biotechnology companies segment captured the largest Middle East and Africa life science market share as these organizations lead in adopting advanced technologies, expanding production capacities, and investing in clinical trials. Rising demand for high-quality research materials, biologics, and therapeutic innovations, along with strategic partnerships with diagnostic and academic institutions, has boosted their market influence. Additionally, the focus on regional market expansion and regulatory compliance initiatives has further reinforced the dominance of pharmaceutical and biotechnology companies as key end-users in the life sciences sector.
The hospital & diagnostic laboratories segment is expected to grow at the fastest CAGR in the Middle East and Africa life science market due to increasing patient demand for advanced diagnostic services and personalized healthcare. Expansion of hospital networks, modernization of laboratory infrastructure, and adoption of innovative testing technologies such as molecular diagnostics and point-of-care testing are driving growth. Additionally, rising government initiatives to improve healthcare accessibility and investment in public and private diagnostic facilities are accelerating the segment’s rapid expansion.
The molecular biology & PCR segment led the Middle East and Africa life science market as it enables rapid, accurate, and high-sensitivity testing for pathogens, genetic mutations, and biomarkers. Growing demand for research in drug discovery, vaccine development, and agricultural biotechnology, along with rising government support for molecular diagnostics infrastructure, has propelled adoption. Furthermore, the segment benefits from increasing collaborations between regional laboratories and international research organizations, driving technological upgrades and broader applications across clinical, academic, and industrial life science settings.
The CRISPR & gene editing segment is expected to register the fastest growth in the Middle East and Africa life science market, as rising collaborations between biotech startups and research institutes accelerate innovation. Growing focus on tackling genetic disorders, enhancing crop traits, and developing next-generation therapies, along with increasing availability of specialized laboratories and funding programs, is driving adoption. The segment’s rapid expansion is further supported by technological advancements that make gene editing more accessible and cost-effective across the region.
The Middle East and Africa life science market is witnessing significant expansion as private sector investments and international collaborations drive innovation. Increasing focus on local biomanufacturing, telemedicine, and digital health solutions is enhancing research and healthcare capabilities. Rising awareness of preventive care, government-backed funding programs, and growing demand for advanced laboratory services are further fueling market growth. Additionally, the adoption of cutting-edge technologies in diagnostics, drug development, and therapeutic research is creating new opportunities across the region.
The global life sciences market is valued at US$ 88.2 billion in 2024 and is expected to grow to US$ 98.63 billion in 2025. Looking ahead, it is projected to reach approximately US$ 269.56 billion by 2034, expanding at a CAGR of 11.82% between 2025 and 2034.
In 2024, GCC countries led the Middle East and Africa life science market as their focus on healthcare modernization, digital health adoption, and strategic public-private partnerships boosted sector growth. Expansion of specialized research institutions, increased funding for biotechnology initiatives, and strong market access for innovative therapies further strengthened their position. Additionally, government incentives encouraging local manufacturing, clinical trials, and regional distribution of life science products helped GCC nations secure the highest revenue share in the market.
Egypt is projected to achieve the fastest CAGR in the Middle East and Africa life science market as rising private sector investments and international partnerships boost research and development activities. Expansion of academic and clinical research centers, growing demand for advanced diagnostics, and government policies supporting innovation in the biotechnology and pharmaceutical sectors are driving growth. Furthermore, increasing awareness of preventive healthcare, adoption of digital health solutions, and initiatives to enhance local manufacturing capabilities are accelerating the country’s market expansion during the forecast period.
By Product Type
By Application
By End-User
By Technology
By Region
October 2025
October 2025
October 2025
October 2025